02nd week of 2014 patent applcation highlights part 24 |
Patent application number | Title | Published |
20140011787 | ANDROGEN TREATMENT IN FEMALES - Method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering an androgen, such as dehydroepiandrosterone or testosterone, to the female for at least about one month, and then evaluating a second anti-Müllerian hormone level of the female. Change in the anti-Müllerian hormone level is indicative of change in the ovarian reserve, e.g., when the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level, the ovarian reserve has improved. The androgen administration may continue until the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level by a desired percentage or amount. | 2014-01-09 |
20140011788 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM - A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition. | 2014-01-09 |
20140011789 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPOSITIONS COMPRISING SAME - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 2014-01-09 |
20140011800 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. | 2014-01-09 |
20140011801 | HETEROARYL QUINAZOLINE DERIVATIVES - Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. | 2014-01-09 |
20140011804 | BICYCLIC PKM2 ACTIVATORS - Compounds and compositions comprising compounds including formula (I) that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer. | 2014-01-09 |
20140011805 | INHIBITORS OF THE BMP SIGNALING PATHWAY - The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. | 2014-01-09 |
20140011808 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS - 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms. | 2014-01-09 |
20140011809 | DRUG DELIVERY TO THE ANTERIOR AND POSTERIOR SEGMENTS OF THE EYE USING EYE DROPS - A method and means for delivery of drugs to the chorio-retina and the optic nerve head which comprises contacting the surface of the eye with an effective amount of drug for treatment of chorio-retina and optic nerve head and a physiologically acceptable adrenergic agent for enhancing delivery of the drug to these tissues in an ophtalmologically acceptable carrier, said adrenergic agent being selected from the group consisting of alpha adrenergic agonist agents, derivatives of the alpha adrenergic agonist agents, beta-blocking agents, derivatives of the beta-blocking agents and mixtures thereof. | 2014-01-09 |
20140011810 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith - Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith. | 2014-01-09 |
20140011811 | MYOSIN BINDING PROTEIN-C FOR USE IN METHODS RELATING TO DIASTOLIC HEART FAILURE - The invention provides methods relating to the diagnosis and treatment of diastolic heart failure, kits for diagnosing diastolic heart failure or diastolic dysfunction, and related systems, computer readable storage media, and methods implemented by a processor in a computer. | 2014-01-09 |
20140011814 | DIAMINE AND MEGLUMINE SALT FORMS OF FATTY ACIDS - Provided herein are diamine salts of eicosapentaenoic acid and docosahexaenoic acid, processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and the uses of such compounds as agents for treating dyslipidemia, cardiovascular diseases such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke and obesity. | 2014-01-09 |
20140011815 | FITNESS ASSAY AND ASSOCIATED METHODS - The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R | 2014-01-09 |
20140011816 | NOVEL SUBSTITUTED TRIAZOLYL PIPERAZINE AND TRIAZOLYL PIPERIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS - The present invention is concerned with novel substituted triazolyl piperazine and triazolyl piperidine derivatives of Formula (I) | 2014-01-09 |
20140011817 | COMPOSITION FOR REDUCING NERVOUS SYSTEM INJURY AND METHOD OF MAKING AND USE THEREOF - This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof. | 2014-01-09 |
20140011818 | ENANTIOMERS OF FLUCONAZOLE ANALOGUES CONTAINING THIENO-[2,-3-D]PYRIMIDIN-4(3H)-ONE MOIETY AS ANTIFUNGAL AGENTS - The present invention discloses novel enantiomeric antifungal compounds of Formula (1a) and Formula (1b) containing thieno-[2,3-d]Jpyrimidin-4(3H)-one moiety and pharmaceutically acceptable salts thereof, method of preparing these compounds, the use of these compounds in prevention and treatment of fungal infections, and pharmaceutical preparations containing these compounds. | 2014-01-09 |
20140011819 | NOVEL SELECTIVE PI3K DELTA INHIBITORS - The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them. | 2014-01-09 |
20140011820 | USE OF ALLOPURINOL FOR THE TREATMENT OF PALMAR PLANTAR ERYTHRODYSESTHESIA - Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of palmar plantar erythrodysesthesia induced by chemotherapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream. | 2014-01-09 |
20140011821 | EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment. | 2014-01-09 |
20140011822 | METHODS AND MATERIALS FOR REDUCING VENOUS STENOSIS FORMATION OF AN ARTERIOVENOUS FISTULA OR GRAFT - This document provides methods and materials for reducing venous stenosis formation of an arteriovenous fistula or graft. For example, methods and materials for using VEGF inhibitors to reduce venous stenosis formation of arteriovenous fistulas or grafts are provided. | 2014-01-09 |
20140011823 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME - The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPARγ activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R | 2014-01-09 |
20140011824 | N1-SUBSTITUTED-5-FLUORO-2-OXOPYRIMIDINONE-1(2H)-CARBOXAMIDE DERIVATIVES - This present disclosure is related to the field of N1-substituted-5-fluoro-2-oxopyrimidinone-1-(2H)-carboxamides and their derivatives and to the use of these compounds as fungicides. | 2014-01-09 |
20140011825 | Compounds and Compositions as Protein Kinase Inhibitors - The present invention provides compounds of Formula I or II: | 2014-01-09 |
20140011826 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE - Use of a metabotropic glutamate receptor group I antagonist, or a pharmaceutically acceptable salt, prodrug or an optical isomer thereof, for the manufacture of a medicament for the treatment or the prevention of abnormal union of tissue, is provided. A related method is also provided. | 2014-01-09 |
20140011827 | PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS - The present invention is directed to piperidinone carboxamide spirohydantoin derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 2014-01-09 |
20140011828 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 2014-01-09 |
20140011829 | Artemisinin-Based Combination Therapy For Treating Viral Mediated Disease - The present invention describes a method of treating individuals suffering from microbial infections, including a viral infection such as Dengue Fever, using an improved Artemisinin Combination Therapy (ACT), known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is then administered to the individual. | 2014-01-09 |
20140011830 | Artemisinin-Based Combination Therapy For Treating Parasitic Mediated Disease - The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy, known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. | 2014-01-09 |
20140011832 | Encased Tamper Resistant Controlled Release Dosage Forms - In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C. | 2014-01-09 |
20140011833 | CAMPTOTHECIN DERIVATIVES HAVING ANTI-TUMOR ACTIVITY - Disclosed are novel camptothecin derivatives having anti-tumor activity (the basic structure thereof is as shown in the figure) and compositions of such compounds and use thereof. The compounds according to the present invention exhibit very good water solubility and stability, show good selectivity among drugs of the same category, and have a very high therapeutic index. Such compounds are promising as therapeutic agents for treating tumors. | 2014-01-09 |
20140011834 | STABLE FORMULATIONS, AND METHODS OF THEIR PREPARATION AND USE - Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability. | 2014-01-09 |
20140011835 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES - The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or prophylaxis of a neurodegenerative or hematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or hematological disease or condition, and a pharmaceutical composition comprising the compounds. | 2014-01-09 |
20140011836 | METHOD OF TREATING NEUROPATHIC PAIN - Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain. | 2014-01-09 |
20140011837 | COMPOSITIONS AND METHODS FOR TREATING WARTS ASSOCIATED WITH VIRAL INFECTIONS - The invention provides compositions and methods for the treatment, as well as the inhibition and prevention, of an infection of the human papillomavirus and the epithelial lesions, namely, the warts of the skin and mucosal surfaces, associated therewith. The compositions comprise a therapeutically effective amount of an active ingredient comprising a compound selected from the group consisting of chloroquine, hydroxychloroquine, chloroquine combined with amodiaquine, and hydroxychloroquine combined with amodiaquine, or in each case, a pharmaceutically acceptable salt thereof. The methods comprise topically administering a therapeutically and/or antivirally effective amount of such a compound to a human being in need of such treatment, although in certain of the compounds may alternatively be administered subcutaneously or transdermally. The compositions may optionally also comprise one or more pharmaceutically acceptable non-active ingredients. | 2014-01-09 |
20140011838 | COMPOSITIONS AND METHODS FOR TREATING WARTS ASSOCIATED WITH VIRAL INFECTIONS - The invention provides compositions and methods for the treatment, as well as the inhibition and prevention, of an infection of the human papillomavirus and the epithelial lesions, namely, the warts of the skin and mucosal surfaces, associated therewith. The compositions comprise a therapeutically effective amount of an active ingredient comprising at least one compound selected from the group consisting of chloroquine, hydroxychloroquine, amodiaquine, or in each case, a pharmaceutically acceptable salt thereof. The methods comprise topically administering a therapeutically and/or antivirally effective amount of such a compound to a human being in need of such treatment, although in certain of the compounds may alternatively be administered subcutaneously or transdermally. The compositions may optionally also comprise one or more pharmaceutically acceptable non-active ingredients. | 2014-01-09 |
20140011839 | COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS - Compositions and methods for the treatment, as well as the inhibition and prevention, of an infection of the papillomavirus and the epithelial lesions, namely, the warts of the skin and mucosal surfaces, associated therewith, in a mammalian host, as well as methods of inhibiting the replication of a papillomavirus in an infected cell, are provided. The compositions comprise a therapeutically effective amount of an active ingredient comprising at least one compound selected from the group consisting of chloroquine, hydroxychloroquine, amodiaquine, or in each case, a pharmaceutically acceptable salt thereof. The methods comprise topically administering a therapeutically and/or antivirally effective amount of such a compound to a mammalian host, such as a human being, in need of such treatment, although alternatively other routes of administration may be used, including but not limited to transdermal, transmucosal, respiratory, and by injection. The compositions optionally also comprise one or more pharmaceutically acceptable non-active ingredients. | 2014-01-09 |
20140011840 | Compounds of Modulating TRPV3 Function - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. | 2014-01-09 |
20140011841 | TREATMENT OF ENERGY UTILIZATION DISEASE - Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon. | 2014-01-09 |
20140011842 | Oral Pharmaceutical Dosage Forms - Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided. | 2014-01-09 |
20140011843 | METHODS FOR STABILIZING OXIDATIVELY UNSTABLE COMPOSITIONS - Ophthalmic compositions and methods of preparing such compositions are disclosed. | 2014-01-09 |
20140011844 | MIGRASTATIN ANALOGS AND USES THEREOF - The present invention provides compounds having formula (I): | 2014-01-09 |
20140011845 | CHEMICAL COMPOUNDS - Disclosed are cyclic dione derivatives represented by formula (I), wherein the substituents are as defined in the description. The preparation method, intermediate and use thereof are also provided. | 2014-01-09 |
20140011846 | Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl) Benzoic Acid - The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. | 2014-01-09 |
20140011847 | CASPASE INHIBITORS AND USES THEREOF - This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6. | 2014-01-09 |
20140011848 | INSULIN SENSITISERS AND METHODS OF TREATMENT - The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods. | 2014-01-09 |
20140011849 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF - The present invention provides a compound represented by the formula | 2014-01-09 |
20140011850 | Methods Of Improving Cognitive Function - A method of improving cognitive function or treating cognitive dysfunction is provided. The method is based on activating a kainate receptor or a glutamate GluR6 receptor by kainate or a glutamate GluR6 receptor activator such as an agonist. Additionally, a method of enhancing a learning ability by activating a kainate receptor such as the glutamate GluR6 receptor via kainate or a glutamate GluR6 receptor activator such as an agonist is provided. | 2014-01-09 |
20140011851 | Novel crystals and process of making 5-(-METHYL)-2-METHOXY-BENZOIC ACID - The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. | 2014-01-09 |
20140011852 | "AMINOINDANES AMIDES HAVING A HIGH FUNGICIDAL ACTIVITY AND THEIR PHYTOSANITARY COMPOSITIONS" - New aminoindanes amides are described, having general formula (I) | 2014-01-09 |
20140011853 | SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY - The invention relates to substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones of the formula (Ia) for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders. | 2014-01-09 |
20140011854 | ST-246 Liquid Formulations and Methods - The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation. | 2014-01-09 |
20140011855 | POLYMER-SEMAXANIB MOIETY CONJUGATES - The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form. | 2014-01-09 |
20140011856 | SALT FORM OF TYROSINE KINASE INHIBITOR - Provided are acid addition salts of (Z)—N-[2-(diethylamino)ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indol-3-ylidene)-4,5,6,7-tetrahydro-1H-indol-3-carboxamide, wherein the salt comprising at least one of a number of salts including L-malate, hydrochloride, phosphate, L-tartrate, benzenesulfonate, sulfate, methanesulfonate, succinate, citrate, fumarate, p-toluenesulfonate, hydrobromate, L-mandelate, lactate, acetate or maleate salt. Also provided is a pharmaceutical composition comprising the salt compounds, and a method of treatment by administering a therapeutically effective amount of the salt compounds as preparation of medicaments. | 2014-01-09 |
20140011857 | SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS - The invention provides for novel compounds which are inhibitors of lysine-specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer. | 2014-01-09 |
20140011858 | Inhibitor of IRS-1 for Treating Skin Disorders - The present invention relates to an inhibitor of the expression of IRS-1 for treating an angiogenic and/or inflammatory skin disease. The present invention also relates to a transdermal composition, preferably an ointment, comprising an inhibitor of the expression of IRS-1, and to the use thereof for treating an angiogenic and/or inflammatory skin disease. | 2014-01-09 |
20140011859 | ANTIMIR-451 FOR THE TREATMENT OF POLYCYTHEMIAS - The present invention provides methods of treating diseases and disorders associated with aberrant erythropoiesis. Specifically, the present invention provides a method for treating polycythemia in a subject by administering an inhibitor of miR-451. Methods of increasing red blood cell count and treating anemia in a subject by administering miR-451 mimetics are also disclosed. | 2014-01-09 |
20140011860 | COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS - Compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells are provided. The compounds and methods modulate target nucleic acids in a sub-nuclear organelle include, but are not limited to, the nucleolus and/or a cajal body of animal cells. | 2014-01-09 |
20140011861 | Materials and Methods for Determining Diagnosis and Prognosis of Prostate Cancer - Materials and methods related to diagnosing and/or determining prognosis of prostate cancer. | 2014-01-09 |
20140011862 | Compositions and Methods for Treating Leukemia - The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject. | 2014-01-09 |
20140011863 | METHODS AND COMPOSITIONS FOR ASSESSMENT OF PULMONARY FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing chronic obstructive pulmonary disease (COPD), emphysema or both COPD and emphysema in smokers and non-smokers using analysis of genetic polymorphisms. | 2014-01-09 |
20140011864 | TRANSITION METAL COMPLEXES OF A BIS[THIOHYDRAZIDE AMIDE] COMPOUND - The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof. | 2014-01-09 |
20140011865 | SOLID STATE FORMS OF CABAZITAXEL AND PROCESSES FOR PREPARATION THEREOF - The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer. | 2014-01-09 |
20140011866 | AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY - Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer. | 2014-01-09 |
20140011867 | EFFECT OF BORRELIDIN FOR CONTROLLING SOYBEAN PHYTOPHTHORA ROOT ROT - The present invention discloses use of borrelidin for preventing and controlling | 2014-01-09 |
20140011868 | Use of Simalikalactone E as an Anticancer Agent - The invention relates to Simalikalactone E (SkE) to be used for preventing and/or treating cancers. | 2014-01-09 |
20140011869 | COMPOSITIONS AND METHODS OF TREATMENT WITH PROANTHOCYANIDIN POLYMER ANTIDIARRHEAL COMPOSITIONS - Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a | 2014-01-09 |
20140011870 | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using effective of amounts of a MetAP-2 inhibitor. | 2014-01-09 |
20140011871 | ANTIFUNGAL SERUM - The subject invention is based upon the discovery that an antifungal agent can be delivered through the fingernail or the toenail of an infected human to treat onychomycosis by dissolving or dispersing the antifungal agent in a solvent system which is comprised of a combination of an alkyl lactate and | 2014-01-09 |
20140011872 | FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy. | 2014-01-09 |
20140011873 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects. | 2014-01-09 |
20140011874 | TREATMENT OF VIRAL INFECTIONS - The invention provides low concentration, stable compositions for the treatment of lesions associated with herpes viral infections. The compositions are in a form selected from creams and gels containing trichloroacetic acid in an amount of between 2.5% (m/m) and 6% (w/w) of the weight of the cream or gel. Preferably the cream contains about 5% and the gel about 2.5% of the trichloroacetic acid. | 2014-01-09 |
20140011875 | METHODS AND COMPOSITIONS FOR THE GENERATION OF PERACETIC ACID ON SITE AT THE POINT-OF-USE - Methods and compositions for the generation of a peroxyacetic acid sanitizer in proximity to the point-of-use are disclosed. These methods comprise introducing a hydrogen peroxide-acetyl precursor solution to water, mixing, and then adding an aqueous source of a alkali metal or earth alkali metal hydroxide. Triacetin is a preferred acetyl precursor and is converted rapidly and with a high conversion rate into peracetic acid. These methods produce solutions with a high level of peracetic acid. Methods for preparing the hydrogen peroxide-acetyl precursor solution are also provided. Also disclosed are solid compositions comprising a liquid acetyl precursor, a water-soluble source of hydrogen peroxide, and a water-soluble source of alkalinity. The solid composition is a freely-flowable solid that is used as a bleaching agent and a stain remover for the treatment of articles such as fabrics, dentures, textile garments, and equipment used in the food and beverage industry. | 2014-01-09 |
20140011876 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract. | 2014-01-09 |
20140011877 | COMPOSITION FOR ACCELERATED PRODUCTION OF COLLAGEN - Here the inventors provide a composition for topical application to the skin of animal comprising stearidonic acid in combination with one or more octadecatrienoic acids (CODTAs). Preferably the composition comprises | 2014-01-09 |
20140011878 | HIGH-DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS - The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment. | 2014-01-09 |
20140011879 | SERUM MARKERS FOR IDENTIFICATION OF CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS - Tools for diagnosis and management of patients suspected of having or having been previously diagnosed with systemic sclerosis are based on the determination one or more of the markers described herein, specifically, the markers having the amino acid sequence of SEQ ID NOS: 1-62 and 66-76 in a sample from the subject. Specific marker ratios and subsets of markers and ratios identify a patient and further subclassify the patient. The information may be used prospectively to study the response of subclassified patients to existing or novel therapeutic strategies. | 2014-01-09 |
20140011880 | POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. | 2014-01-09 |
20140011881 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. | 2014-01-09 |
20140011882 | COMPOSITION OF 5-NITROBENZOATE DERIVATIVES AS ANTI-METASTATIC AGENT THAT INHIBITS TUMOR CELL-INDUCED PLATELET AGGREGATION - Disclosed are 5-nitrobenzoate derivatives of Formula I, | 2014-01-09 |
20140011883 | CRYSTAL FORM VII OF AGOMELATINE, PREPARATION METHOD AND USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention provides a new crystalline form VII of agomelatine, its method of preparation, application and pharmaceutical composition. This new crystalline form offers high purity, a stable crystalline structure and good reproducibility, while its method of production lends itself well to large scale production. In terms of stability and purity, it is superior to the numerous crystalline forms which have hitherto been reported. As a result, the crystalline form VII of the present invention possesses advantages in pharmaceutical preparation. | 2014-01-09 |
20140011884 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression. | 2014-01-09 |
20140011885 | Organic Compounds - A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol. | 2014-01-09 |
20140011886 | Crystalline Forms of (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride - A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. | 2014-01-09 |
20140011887 | MATERIALS AND METHODS FOR IMPROVING ALCOHOL METABOLISM AND ALLEVIATING THE EFFECTS OF HANGOVERS - The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride. | 2014-01-09 |
20140011888 | COMPOSITION DERIVED FROM ASTAXANTHIN AND METHOD TO TREAT JOINT PAIN ASSOCIATED WITH OSTEOARTHRITIS - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 2014-01-09 |
20140011889 | Resveratrol-Containing Compositions and Methods of Use for Cardiac-Related Diseases - A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D. | 2014-01-09 |
20140011890 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES - Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuin AMPK activity, LKB | 2014-01-09 |
20140011891 | MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES - Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A | 2014-01-09 |
20140011892 | PEARL SUGAR PARTICLE, COMPOSITION, AND PROCESS FOR PREPARING A PEARL SUGAR - A pearl sugar particle includes granulated sugar and at least one additive, wherein the at least one additive is distributed homogeneously throughout the pearl sugar particle. A composition including a plurality of pearl sugar particles and a process for preparing a pearl sugar are also disclosed. | 2014-01-09 |
20140011893 | COMPOSITION AND METHOD - A method of preparing a mucoadhesive film formulation by preparing a film forming composition including lambda carrageenan as a film forming polymer, at a concentration of about 1-7% by weight, a plasticizer at a concentration of about 1-15% by weight, a biologically active substance, and purified water; distributing the film forming composition as a wet film layer onto a solid surface; and allowing the film layer to dry. A mucoadhesive film obtained by the method and a film dosage unit. | 2014-01-09 |
20140011894 | Stable Emulsions of Personal Care Products - Natural extracts of spearmint and rosemary, together with hydrolyzed lecithin, are used to formulate a natural tinted moisturizer with more that 96% natural/nature-derived raw materials. Color pigments are suspended in the emulsion system thickened by xanthan gum. The process uses a combination of mixing with a homogenizer and a multi-speed stirrer. Stability is observed in accelerated conditions. The product results with an excellent emulsion stability. The hydrolyzed lecithin is liquid at room temperature. This study demonstrates that it is an easy to use emulsifier in cold-processed emulsions with a thickener system that can be dispersed and activated at room temperature. The hydrolyzed lecithin was used to emulsify blends of oils into a stable lotion for the cosmetic and personal care markets. The emulsion was found to be highly stable when centrifuged and studied at accelerated stability conditions | 2014-01-09 |
20140011895 | BIOMARKERS FOR SYSTEMIC LUPUS ERYTHEMATOSUS - The disclosure provides novel SLE biomarkers. The disclosure further provides kits and methods of diagnosing, prognosing, and stratifying subjects with the disease by utilizing the novel SLE biomarkers. | 2014-01-09 |
20140011896 | METHOD FOR STOPPING OPERATION OF REACTOR - The method for stopping operation of a reactor is provided with a stop step of stopping supply of a synthesis gas containing a carbon monoxide gas and a hydrogen gas into the reactor; a slurry discharge step of discharging slurry from the reactor; a steam supply step of supplying steam higher in temperature than the decomposition temperatures of metal carbonyls into the reactor, thereby discharging gaseous matters inside the reactor; and a carbon monoxide gas detecting step of detecting an amount of carbon monoxide gas contained in the gaseous matters discharged from the reactor. In the steam supply step, supply of the steam is stopped when an amount of the detected carbon monoxide gas continuously declines to be lower than a predetermined reference value. | 2014-01-09 |
20140011897 | REACTION MIXTURE IN THE FORM OF AN EMULSION AND PROCESS FOR PRODUCTION OF POLYURETHANE FOAMS FROM SUCH A REACTION MIXTURE - The present invention relates to a reaction mixture in emulsion form, suitable for conversion into polyurethanes, comprising a first phase and a second phase in the emulsion and further comprising the following components: A) polyols; B) blowing agent; C) surfactants; and D) isocyanates, wherein the isocyanate-reactive compounds A) are present in the first phase of the emulsion and the blowing agent B) is present in the second phase. The blowing agent B) is present in the near-critical or supercritical state and the isocyanate D) is present in the second phase in a proportion of ≧10% by weight of the total amount of isocyanate D) in the composition. The invention further relates to a method of producing polyurethane foams by providing such a reaction mixture, wherein a polymerization takes place at the freshly formed interface between the polyol phase and the blowing agent phase, to the use of such a reaction mixture for producing polyurethane foams and also to the polyurethane foams obtained. | 2014-01-09 |
20140011898 | THERMOPLASTIC ELASTOMERS WITH SILKY FEEL - A thermoplastic elastomer compound is blended from styrenic block copolymer, thermoplastic vulcanizate, thermoplastic polyurethane, a compatibilizer, and a masterbatch containing silicone, which is added to provide a qualitative silky feel on surfaces of plastic articles made from the compound. | 2014-01-09 |
20140011899 | DEFORMABLE, RIGID POLYSTYRENE FOAM BOARD - Provided are methods for producing a high strength, but easily deformed, polystyrene foam board that can endure repeated deformations from its original configuration into more complex curved shapes without damaging the board integrity or substantially reducing its structural strength. Also provided are rigid polystyrene foam boards produced by this method that exhibit improved bending and impact resistance while substantially retaining or improving other properties, for example, the thermal dimensional stability and fire resistance, exhibited by corresponding conventional XPS foam boards. The foamable compositions may incorporate one or more of a variety of polymer processing aids for the purpose of altering the performance of the final foam products, thereby allowing the properties of the final foam product to be customized to some degree. | 2014-01-09 |
20140011900 | Method for Producing Silyl-Functionalized Polyolefins and Silyl-Functionalized Polyolefins with Silyl Monomer Incorporation - Methods for producing a silyl-functionalized polyolefin with silyl monomer incorporation are provided. The method includes reacting a silicon-containing olefin with an α-olefin, in the presence of a catalytic amount of a group IV catalyst for a time sufficient to produce a silyl-functionalized polyolefin. | 2014-01-09 |
20140011901 | Stabilized Polyolefin Compositions - Disclosed are compositions comprising antioxidants and stabilizers, such as, acid scavengers or organic phosphorus stabilizers, and optionally further comprising co-stabilizers. The disclosed compositions are useful as stabilizers for polyolefins and other polymeric materials. The disclosed compositions and methods generally provide longer shelf lifes and better oxidative resistance to materials than currently available antioxidants. | 2014-01-09 |
20140011902 | FOAM WATERPROOFING MATERIAL WITH A MICRO CELL STRUCTURE - To be provided is a foam waterproofing material superior in waterproofness and flexible enough to be compatible with further minute clearance. | 2014-01-09 |
20140011903 | POLYURETHANE POLYMERS AND COMPOSITIONS MADE USING DISCRETE CARBON NANOTUBE MOLECULAR REBAR - In various embodiments a urethane/molecular rebar formulation comprising a specific composition is disclosed. The composition comprises a urethane polymer or prepolymer/discrete carbon nanotube formulation. Utility of the urethane/molecular rebar composition includes improved foams and adhesives. | 2014-01-09 |